Inhaled iloprost for therapy in pulmonary arterial hypertension

Expert Rev Respir Med. 2011 Apr;5(2):145-52. doi: 10.1586/ers.11.14.

Abstract

Iloprost (Ventavis, Bayer Schering Pharma, Germany) is a synthetic prostacyclin that is used in its inhalative form for the therapy of pulmonary arterial hypertension. Long-term therapy can increase exercise capacity and quality of life. The use of modern nebulizers especially designed for the administration of iloprost guarantees the pulmonary deposition of the required doses and systematically minimizes side effects. Regarding existing data, inhalative iloprost acts in effective and safe combination with other classes of medication; indeed, such combination therapy is frequently necessary in pulmonary arterial hypertension.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Animals
  • Antihypertensive Agents / administration & dosage*
  • Antihypertensive Agents / adverse effects
  • Antihypertensive Agents / pharmacokinetics
  • Blood Pressure / drug effects
  • Drug Therapy, Combination
  • Evidence-Based Medicine
  • Familial Primary Pulmonary Hypertension
  • Humans
  • Hypertension, Pulmonary / drug therapy
  • Hypertension, Pulmonary / physiopathology
  • Iloprost / administration & dosage*
  • Iloprost / adverse effects
  • Iloprost / pharmacokinetics
  • Nebulizers and Vaporizers
  • Risk Assessment
  • Treatment Outcome
  • Vasodilation / drug effects
  • Vasodilator Agents / administration & dosage*
  • Vasodilator Agents / adverse effects
  • Vasodilator Agents / pharmacokinetics

Substances

  • Antihypertensive Agents
  • Vasodilator Agents
  • Iloprost